
Benzinga Pro data, VistaGen Therapeutics (NASDAQ:VTGN) reported Q4 sales of $38.90 thousand. Earnings fell to a loss of $16.69 million, resulting in a 58.41% decrease from last quarter. VistaGen Therapeutics collected $357.90 thousand in revenue during Q3, but reported earnings showed a $10.54 million loss.